SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Momenta Pharmaceuticals Inc.
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
3027 64 0 MNTA
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2227politico.com The plot thickens in this tug-of-war.... glad that MNTA wasn'tArthur Radley-3/31/2010
2226Tuck, mpower et al: It’s easy to lose sight of the fact that NVS-ACL is one of tDewDiligence_on_SI13/28/2010
2225But it would be the Sandoz division. Seems like it would be different execs invtuck-3/28/2010
2224The Alcon acquisition is expected to be completed in the second half of 2010. Wmpower90024-3/28/2010
2223In contrast to UFH, Lovenox does not have an unduly narrow therapeutic window (aDewDiligence_on_SI-3/25/2010
2222Not sure if it's directly relevant but nonetheless... April 13 & 14, 20rkrw13/25/2010
2221and only 2 after hours trades although the first one was well above the top of tIan@SI-3/24/2010
2220MNTA’s Barclays presentation today was abruptly canceled: siliconinvestor.com DewDiligence_on_SI-3/24/2010
2219MNTA ‘ReadMeFirst’ updated: <i>major rewrite of section on generic CopaxoDewDiligence_on_SI-3/23/2010
2218I replied to your related iHub post in siliconinvestor.com . Regards, DewDewDiligence_on_SI-3/23/2010
2217I gather this is because of lack of a blood serum level test -- hence PK/PD paratuck-3/23/2010
2216Agree. At this point in their relationship, it probably makes more sense to seeIan@SI-3/19/2010
2215I don’t see NVS making a move to acquire MNTA (or anyone else) until the Alcon dDewDiligence_on_SI-3/19/2010
2214perhaps this is the rationale for today's "green" in a sea of bioIan@SI-3/19/2010
2213<i>>…but as I said, I'm struggling.</i> I’m still not clear DewDiligence_on_SI-3/19/2010
2212"If we don't get approval, I will be very upset and don't care wherJeffry K. Smith-3/18/2010
2211If you read the ReadMeFirst, you'll see that the valuation depends on whethempower90024-3/18/2010
2210<i>>Is there any way you can distill things down further?<</i>DewDiligence_on_SI-3/17/2010
2209I looked over all of the top (most recent) links within your posts at the link yJeffry K. Smith-3/17/2010
2208MNTA ‘ReadMeFirst’ updated: <i>index to posts on competing anticoagulantDewDiligence_on_SI-3/16/2010
2207NVS is the stock ticker for Novartis, MNTA's partner.DewDiligence_on_SI-3/16/2010
2206Dew, As a new poster to this thread, and a new owner of MNTA, I wanted to thankJeffry K. Smith-3/16/2010
2205I asked Rocky what his downside assumptions were if the Lovenox application is frkrw-3/15/2010
2204This thread was about option valuations, right? The Copaxone Markman hearing is DewDiligence_on_SI-3/15/2010
2203I don't expect Copaxone approval without clinical trials, so for me the paterkrw-3/14/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News